Zobrazeno 1 - 10
of 12
pro vyhledávání: '"35"'
Autor:
Mark J. Ratain, Arlene A. Forastiere, Lei Ye, Robert F. Gagel, Ezra E.W. Cohen, Linda Janisch, Steven I. Sherman, Forlisa Nauling, David S. Hong, Chaan S. Ng, Razelle Kurzrock, Thomas Müller, Ranee Mehra, Douglas W. Ball, John W. Frye, David G. Pfister, Roger B. Cohen, Ravi Salgia
Publikováno v:
Journal of Clinical Oncology. 29:2660-2666
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit
Autor:
Apurvasena Parikh, Colin D. Weekes, Monica Motwani, Daniel Morgensztern, Huibin Yue, Edward B. Reilly, John Nemunaitis, Todd M. Bauer, Ramesh K. Ramanathan, Daniel E. H. Afar, Rebecca S. Heist, Karen Kelly, Eric Angevin, John H. Strickler, Louie Naumovski
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 33
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Purpose This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. Materials and Methods For dose escalatio
Autor:
Charles R. Fitz, Minesh P. Mehta, Joanne M. Hilden, Tianni Zhou, Nancy J. Tarbell, Joel W. Goldwein, Arzu Onar, Roger J. Packer, Regina I. Jakacki, Emiko J. Holmes, Peter C. Burger, Ian F. Pollack, Mehmet Kocak, Gilbert Vezina
Publikováno v:
Journal of Clinical Oncology. 30:2648-2653
Purpose We evaluated the feasibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy (CSRT) to patients with high-risk medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumors, and we report t
Autor:
Simon J. Harrison, H. Miles Prince, Anna Sureda, Patrick B. Johnston, Dina Ben-Yehuda, Anas Younes, Pier Luigi Zinzani, Christophe Le Corre, Angela Shen, Andreas Engert, Tee Chuan Ong, Jennifer Gallagher, Mark Kirschbaum
Publikováno v:
Journal of Clinical Oncology. 30:2197-2203
Purpose Hodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population. Patients and Meth
Autor:
Frank V. Fossella, Roy S. Herbst, Rebecca Paulus, Walter J. Curran, Hak Choy, Philip O. Doescher, George R. Blumenschein, Ritsuko Komaki, Maria Werner-Wasik, Francisco Robert
Publikováno v:
Journal of Clinical Oncology. 29:2312-2318
Purpose Non–small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical model
Autor:
Jodi Virkus, Richard Stone, Francis J. Giles, Carlo Lanza, Daniel J. DeAngelo, D. Gary Gilliland, Eric J. Feldman, Gerhard Ehninger, Alice Huntsman-Labed, Edward Fox, Virginia M. Klimek, Stephen D. Nimer, Catherine Dutreix, Thomas Fischer, Ilene Galinsky, Gary J. Schiller, Elihu H. Estey
Publikováno v:
Journal of Clinical Oncology. 28:4339-4345
Purpose Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinas
Autor:
Dennis F. Moore, Primo N. Lara, Zelanna Goldberg, Quynh-Thu Le, John Crowley, James J. Moon, Mary W. Redman, Laurie E. Gaspar, Stephen K. Williamson, David R. Gandara
Publikováno v:
Journal of Clinical Oncology. 27:3014-3019
Purpose A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in limited-stage small-cell lung cancer (LSCLC). We report results of the phase II stud
Autor:
Ana Lluch, Monica Fornier, David Lebwohl, Edgardo Rivera, Linda T. Vahdat, Patrice Viens, José Baselga, Eva Thomas, Valentina Guarneri, Valerie Poulart, Josep Tabernero, J. Klimovsky, Pierfranco Conte, Howard A. Burris, Miguel Martin, Craig A. Bunnell, Pierre Fumoleau
Publikováno v:
Journal of Clinical Oncology. 25:3399-3406
Purpose Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing apo
Autor:
Anthony Polverino, Chaan Ng, Marilyn Mulay, Michael Bass, Robert S. Benjamin, Razelle Kurzrock, Roy S. Herbst, Andy Van Vugt, Michelle Purdom, Antonis Koutsoukos, Jeffrey M. Silverman, Lee S. Rosen, Jeffrey S. Wiezorek, Ren Y. Xu, David D. Chang, Yu Nien Sun
Publikováno v:
Journal of Clinical Oncology. 25:2369-2376
Purpose AMG 706 is an investigational, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and stem-cell factor receptor. This phase I, dose-finding study evaluated the s
Autor:
Judith G, Villablanca, Mark D, Krailo, Matthew M, Ames, Joel M, Reid, Gregory H, Reaman, C Patrick, Reynolds, Patrick C, Reynolds
Publikováno v:
Journal of Clinical Oncology. 24:3423-3430
PurposeTo determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors.MethodsChildren 21 years of age or younger received daily doses from 350 m